Pharma and Biotech
Period Ending | Period | Revenue (£m) | Pre-tax (£m) | EPS | Dividend |
---|---|---|---|---|---|
30-Jun-24 | Q3 | 30.69 | (9.42) | (1.34)p | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-19 | 124.01 | (58.48) | (10.72)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-20 | 105.57 | (22.57) | (3.80)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-21 | 125.06 | (9.18) | (1.93)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-22 | 157.71 | (21.38) | (4.34)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-23 | 169.48 | (12.69) | (2.41)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-24 | 157.10 | 7.95 | (1.00)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-25 | 170.60 | 16.35 | 1.00p | 35.6 | n/a | n/a | n/a | 0.0% |
30-Sep-26 | 191.75 | 24.15 | 1.70p | 20.9 | 0.3 | +70% | n/a | 0.0% |
Copyright © 2024 FactSet Research Systems Inc. All rights reserved.
5 Yr High | 5 Yr Low | 5 Yr Avg | Curr / Avg | |
---|---|---|---|---|
Latest | n/a | n/a | n/a | 0 |
Find out about IFRS and how this affects the financial infomation for all UK companies.
Currency | UK Pounds |
Share Price | 35.60p |
Change Today | -3.40p |
% Change | -8.72 % |
52 Week High | 48.00 |
52 Week Low | 34.00 |
Volume | 118,205 |
Shares Issued | 739.79m |
Market Cap | £263.37m |
Beta | 0.48 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 1 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
13:45 | 3 @ 35.64p |
12:40 | 44 @ 36.00p |
11:41 | 5,682 @ 36.00p |
11:41 | 6,318 @ 36.00p |
11:38 | 7,236 @ 35.61p |
Chair | Peter George |
CFO | Septima Maguire |
CEO | Trond Williksen |
You are here: research